Trial Profile
Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2014
Price :
$35
*
At a glance
- Drugs HIV vaccine-PX-Therapeutics (Primary) ; HIV vaccine-PX-Therapeutics (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors PX Therapeutics
- 20 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jan 2012 New trial record